Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate

Summary

The purpose of this study is to determine the safety, tolerability and efficacy of natalizumab in subjects diagnosed with moderate to severe rheumatoid arthritis (RA) receiving concomitant treatment with methotrexate (MTX). It is thought that natalizumab may stop the movement of certain white blood cells, known as lymphocytes, into joint tissue. These cells are thought to cause damage in the joints leading to the symptoms of RA.

Timeline

Start

2004-05

Primary completion

2005-02

Completion

—

Drugs

Indications